Advances in the Pharmaceutical Treatment of Cardiovascular Disease
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1806
Special Issue Editors
Interests: clinical pharmacology; hypertension; cardiovascular diseases; lipid metabolism; nutrition
Interests: endothelial dysfunction mechanisms; cardiovascular diseases; oxidative stress; biomarkers; homocysteine; anticoagulants
Special Issue Information
Dear Colleagues,
It is important to note that while cardiovascular disease is a significant health problem worldwide, many cases can be prevented or effectively managed with the right lifestyle choices and medical interventions. Regular check-ups and discussions with health professionals are crucial for the early detection, prevention, and treatment of cardiovascular disease. Preventive measures for cardiovascular disease include adopting a healthy lifestyle with a balanced diet and regular exercise, avoiding tobacco and excessive alcohol consumption, and managing underlying medical conditions such as high blood pressure and diabetes. Treatment may involve lifestyle changes, medication, and, in severe cases, surgical interventions. It is widely acknowledged that the latest progress in pharmaceutics has enabled the creation of novel medications targeting cardiovascular illnesses. These advancements have the potential to markedly enhance both immediate and extended prognoses, as well as avert untimely fatalities. Consequently, we cordially invite you to submit your original articles and/or review papers to this Special Issue, whose primary objective is to highlight the advances made in contemporary pharmaceutics for cardiovascular diseases over the past few years.
In this Special Issue, entitled “Advances in the Pharmaceutical Treatment of Cardiovascular Disease”, research areas will include, but are not limited to, the following: drug delivery systems, targeted therapy for cardiovascular treatment, potential biomarkers in cardiovascular disease, drug design, drug–drug interaction, and mechanism studies.
We look forward to receiving your contributions.
Dr. Magdalena Cuciureanu
Dr. Nina Filip
Dr. Cristina-Elena Iancu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- biomarkers
- cardiovascular diseases
- hypertension
- nanotechnology
- stem cells
- treatment modality
- drugs
